People · Operator

William K. McVicar, Ph.D.

Named in public records as an officer, director or promoter · active 2010–2010 · Pharmaceuticals

1
Companies
2
Filings
$37.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Inotek Pharmaceuticals CorpPharmaceuticalsSeries B$37.9M$802.5M2010
Operator network

William K. McVicar, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Argeris ("Jerry") N. Karabelas, PhD · 1 companies · 1 sharedArgeris ("Jerry")…Atul N. Saran · 1 companies · 1 sharedAtul N. SaranIttai Flanagan Harel · 1 companies · 1 sharedIttai Flanagan Ha…Ittai N. Harel · 1 companies · 1 sharedIttai N. HarelJames G. Ham, III · 1 companies · 1 sharedJames G. Ham, IIIJohn Flanagan Leaman · 1 companies · 1 sharedJohn Flanagan Lea…John N. Leaman · 1 companies · 1 sharedJohn N. LeamanMaggie Flanagan LeFlore, PhD · 1 companies · 1 sharedMaggie Flanagan L…Martin N. Vogelbaum · 1 companies · 1 sharedMartin N. Vogelba…Michael D. Loberg, PhD · 1 companies · 1 sharedMichael D. Loberg…Paul G. Howes · 1 companies · 1 sharedPaul G. HowesRudolf A. Baumgartner, MD · 1 companies · 1 sharedRudolf A. Baumgar…Inotek Pharmaceuticals Corp · $37.9M raisedInotek Pharmaceutical…William K. McVicar, Ph.D.WP
William K. McVicar, Ph.D. Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside William K. McVicar, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Michael D. Loberg, PhD11
James G. Ham, III11
Ittai N. Harel11
John N. Leaman11
Rudolf A. Baumgartner, MD11
Paul G. Howes11
Argeris ("Jerry") N. Karabelas, PhD11
Martin N. Vogelbaum11
Atul N. Saran11
Ittai Flanagan Harel11
Maggie Flanagan LeFlore, PhD11
John Flanagan Leaman11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.